NewAmsterdam Pharma Company N.V. Warrant
N/A
USD
N/A
N/A
...
Chart
Financials
Description
NAMSW Company Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
NAMSW Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view NAMSW Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of NAMSW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NAMSW's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of NAMSW in WallStreetBets Daily Discussion
NAMSW News
Recent insights relating to NAMSW
CNBC Recommendations
Recent picks made for NAMSW stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in NAMSW
Corporate Flights
Flights by private jets registered to NAMSW
Our Analysis